Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04288102

Recruitment Status : Completed

First Posted : February 28, 2020

Last Update Posted : August 19, 2020

Sponsor:

Collaborators:

Huoshenshan Hospital

Maternal and Child Health Hospital of Hubei Province

General Hospital of Central Theater Command, Wuhan, China

VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China

Information provided by (Responsible Party):

Fu-Sheng Wang, Beijing 302 Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	May 12, 2020
Actual Study Completion Date :	July 9, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z, Huang L, Fu JL, Li Y, Zhang Y, Yao WQ, Liu T, Song J, Sun L, Yang F, Zhang X, Zhang B, Shi M, Meng F, Song Y, Yu Y, Wen J, Li Q, Mao Q, Maeurer M, Zumla A, Yao C, Xie WF, Wang FS. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021 Feb 10;6(1):58. doi: 10.1038/s41392-021-00488-5.

To Top